Monitoring Agency Report for the quarter ended 31st March, 2026
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CRISIL Ratings Limited has filed the Q4 FY2026 Monitoring Agency Report for Suven Life Sciences' Rs 857.64 crore preferential issue of convertible warrants (allotted June 2025). Of the total issue proceeds, Rs 76,432.52 lakhs has been received; Rs 9,331.50 lakhs is still pending from warrant holders (conversion deadline: December 2026). As of March 31, 2026, Rs 26,068.64 lakhs (30.4%) has been utilized, leaving Rs 59,695.38 lakhs unutilized. Deployment includes: Rs 18,878.64 lakhs toward clinical development via US subsidiary Suven Neurosciences Inc.; Rs 4,039.99 lakhs toward Drug Discovery R&D; Rs 298.72 lakhs toward a new R&D Centre (very low utilization); and Rs 2,851.29 lakhs toward general corporate purposes. The unutilized balance of Rs 50,860.24 lakhs is deployed across liquid mutual funds (Rs 22,121.14 lakhs) and SBI fixed deposits (Rs 27,500 lakhs), earning returns of 5.6-7.2%. The MA confirms all utilization is as per disclosed objects, with no material deviations or unfavorable events noted.
The slow deployment toward the new R&D Centre (only 1.5% utilized) suggests a potential timeline extension for that object. The large unutilized balance is being conservatively deployed in low-risk instruments, which is standard practice. No red flags from the monitoring agency — proceeds are tracking disclosed objectives.